Deal Watch: Gilead Hopes Glympse’s Synthetic Biomarkers Can Optimize NASH Trials
Executive Summary
Gilead partners with Glympse to optimize NASH trials, while Ironwood will work with Pear on digital therapies for GI disorders. An alliance between Leo and Ubiquigent yields an option agreement around two novel compounds.